RESUMO
Background Melanoma is the most aggressive form of skin cancer, accounting for 3% of all malignant cancers. Phytochemicals and their related compounds are found in various parts of the plant Eichhornia crassipes and have a variety of pharmacological actions. The current research was intended to compare and evaluate the anti-proliferative action of methanolic extracts of E. crassipes roots and petioles against the Sloan Kettering Melanoma (SK-Mel-5) cell line. Materials and methods The waters around Ezhikkara, Ernakulum, Kerala, were discovered to contain E. crassipes. We used a Soxhlet extractor to get this concentrated liquid. For this test, we employed a methanolic extract of roots and petioles to determine the extent to which different concentrations of the extract inhibited cell proliferation. Data on absorbance were reported as a mean standard deviation. Using Probit analysis, the IC50 was calculated by evaluating the gradient of the regression line to get a value. Results Concentrations of methanolic root and petiole extracts of 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, and 200 µg/ml were analyzed. The methanol petiole extract reduced the viability of SK-Mel-5 cells more than the root extract, with IC50 values of 323.59 µg/ml and 174.70 µg/ml of the test sample concentration, respectively. The regression equation for the root extract was y = -0.1264x + 90.902 and R2 = 0.845, and for the petiole extract, it was y = -0.2187x + 88.206 and R2 = 0.917. Conclusion The current study found that increasing the concentration of methanolic extracts of roots and petioles of E. crassipes exhibited an increased cell growth inhibition rate. However, methanolic petiole extracts were more cytotoxic than the roots. Thus, the current study demonstrated the therapeutic use of E. crassipes as an anticancer agent, thereby providing a valuable alternative for enabling the early management of melanoma.
RESUMO
INTRODUCTION: Eichhornia crassipes (E. crassipes) are a longstanding hydrophyte belonging to the Pontederiaceae family and subfamily Trollioideae. It is classified as an invasive plant owing to its phenomenal growth and propagation and is often described as the worst aquatic plant. Natural antioxidants, such as phenolic compounds and flavonoids, have an increased protective effect against free radicals. A single laboratory test is insufficient to comprehend all of the mechanisms entailed in investigating the antioxidant effects of the phytoconstituents. The antioxidant propensity of methanolic extracts from E. crassipes petioles was investigated in this study utilizing 2,2'-Azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) and 1,1-diphenyl-2-pycryl-hydrazyl (DPPH). Additionally, the cytotoxic effect of E. crassipes methanolic petiole extract upon MG-63 cell lines for the inhibition of osteosarcoma cells was investigated. MATERIALS AND METHODS: The antioxidant propensity was appraised by employing DPPH and ABTS assays. The cytotoxic effects of the methanolic petiole extract of E. crassipes at varying concentrations on MG-63 cell lines were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. The absorbance scores were computed using the mean and standard deviation. The half-maximal inhibitory concentration (IC50) was calculated by applying probit analysis. The data were analyzed using SPSS Statistics for the descriptive statistics of the percentage of cell viability and regression analysis. RESULTS: The antioxidant potential was assessed by employing DPPH and ABTS assays at various concentration levels of 50 µg/ml, 100 µg/ml, 200 µg/ml, and 400 µg/ml of methanolic petiole extracts. The antioxidant potential of DPPH (57.95%) and ABTS (60.47%) was more at the elevated doses of 400 µg/mL. The percentage of cell viability upon MG-63 cell line was measured at varying doses of 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, and 200 µg/ml of methanolic petiole extracts and was found to be 99.36%, 93.92%, 86.77%, 69.14%, and 45.08%, respectively. The IC50 value for the extract of E. crassipes against the MG-63 cell line was 177.65 µg/mL. The regression equation computed from the findings of the probit analysis was y = -0.2881x + 101.18 with a coefficient of determination of R² = 0.992. CONCLUSION: The methanolic extracts of the various parts of the plant, such as leaves, flower, rhizome, and petioles, have been established in similar prior studies to contain the highest phenolic constituents and were found to have a high rate of DPPH radical scavenging activity and reducing power. It is inferred from the findings of the present study that E. crassipes petiole extracts have a significant protective role against oxidative stress, potentially attributed to the antioxidant potential. Further, the findings of the study reveal that the methanolic petiole extract of E. crassipes induced cytotoxicity upon MG-63 cell lines with an IC50 value of 177.65 µg/mL.
RESUMO
Background Eichhornia crassipes (E. crassipes) have several secondary metabolites that have medicinal value. These include sterols, alkaloids, phenolics, flavonoids, tannins, and saponins. In the current study, the methanolic petiole extract of E. crassipes was examined to determine its potential antiproliferative activity against Sloan Kettering Melanoma 5 (SK-Mel-5) cell lines. Materials and methods Eichhornia crassipes were obtained from the water bodies of Ezhikkara, Ernakulam, Kerala. The Soxhlet technique was used to produce the extract. Leaves, petioles, and roots were dried and pulverized before being analyzed phytochemically in a number of solvents. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure the extent to which various dosages of the extract inhibited cell proliferation, and the methanolic extract of petioles was chosen since it contained more anticancer components. The half maximal inhibitory concentration (IC50) was determined by utilizing a probit model and the slope-gradient method of the regression equation. The Statistical Package for Social Sciences (SPSS) version 21 (IBM SPSS Statistics, Armonk, NY) was used for the analysis. Results We examined the effects of 12.5, 25, 50, 100, and 200 µg/ml of methanolic petiole extract. The data indicated that the methanol extract significantly reduced SK-Mel-5 cell viability. Cell growth inhibition increased with concentration but was shown to be relatively low at 100 g/ml, exhibiting 38.911% of inhibitory activity. The percentage of cell growth inhibition at 200 g/ml was 52.965%. The methanolic petiole extracts of E. crassipes were found to be cytotoxic with IC50 values of 172.186 g/ml. Probit analysis was performed to obtain the regression equation. Conclusion The in vitro study suggests that the methanol extract of the petiole of E. crassipes had modest antiproliferative action against SK-Mel-5 cells, a typical human melanocyte tumor cell line. The study findings shed light on the anticancer activity of E. crassipes, making it an appropriate source of drug-lead chemicals for the development of safer and cost-effective remedies for cutaneous ailments varying from rashes to awful melanoma.
RESUMO
BACKGROUND: An increasing number of people are turning to herbal medicines in their search for innovative pharmaceuticals since they are effective treatments for a wide variety of conditions and traditional herbs are rich in bioactive chemicals. In this study, we looked at whether or not a petiole extract of Eichhornia crassipes preserved in methanol inhibited the proliferation of prostate cancer (PC3) cell lines. MATERIALS AND METHODS: Lakes in Ezhikkara, Ernakulum, Kerala, were the source of E. crassipes. Soxhlet extraction was used to create the extract. 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cell viability of methanolic petiole extract at various concentrations. Mean and standard deviation was used to determine absorbance scores. Utilizing probit analysis, we determined the IC50 value. The descriptive statistics to measure the percent of viable cells along with the regression equation were calculated using SPSS. RESULTS: It has been shown that the methanol extract significantly impacted PC3 cell lines' capacity to survive. It was also determined that increasing the medication concentration resulted in a decrease in cell viability. The percentage of living cells was measured after being exposed to methanol extracts at concentrations of 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, and 200 µg/ml, and found to be 95.13, 85.88, 76.12, 64.33, and 53.62 percent, respectively. With IC50 values of 199.488 g/ml, it was shown that methanolic petiole extracts of E. crassipes are cytotoxic. Using probit analysis, we determined that the regression equation is y = -0.2051x + 90.915, with an R2 value of 0.893. CONCLUSION: As a result of its chemotherapeutic properties, the E. crassipes petiole extract has the potential to be employed in therapeutic applications, with the ultimate goal of bettering prostate cancer management practices and clinical results by drastically lowering cell viability. The study's results may pave the way for fresh chemotherapeutic approaches to be developed for the treatment of androgen-independent prostate cancer.
RESUMO
PURPOSE: The aim of this study was to scale structured report templates categorizing actionable renal findings across health systems and create a centralized registry of patient and report data. METHODS: In January 2017, three academic radiology departments agreed to prospectively include identical structured templates categorizing the malignant likelihood of renal findings in ≥90% of all adult ultrasound, MRI, and CT reports, a new approach for two sites. Between November 20, 2017, and September 30, 2019, deidentified HL7 report data were transmitted to a centralized ACR registry. An automated algorithm extracted categories. Radiologists were requested to addend reports with missing or incomplete templates after the first month. Separately, each site submitted patient sociodemographic and clinical data 12 months before and at least 3 months after enrollment. RESULTS: A total of 164,982 eligible radiology reports were transmitted to the registry; 4,159 (2.5%) were excluded because of missing categories or radiologist names. The final cohort included 160,823 examinations on 102,619 unique patients. Mean template use before and after addendum requests was 99.3% and 99.9% at SITE1, 86.5% and 94.6% at SITE2, and 91.4% and 96.0% at SITE3. Matching patient sociodemographic and clinical data were obtained on 96.9% of reports from SITE1, 94.2% from SITE2, and 96.0% from SITE3. Regulatory, cultural, and technology barriers to the creation of a multisite registry were identified. CONCLUSIONS: Barriers to the adoption of unified structured report templates for actionable kidney findings can be addressed. Deidentified report and patient data can be securely transmitted to an external registry. These data can facilitate the collection of diverse evidence-based population imaging outcomes.